Sweden-based Nanexa has reported preclinical data for a long-acting semaglutide formulation developed using its atomic layer deposition drug delivery platform, PharmaShell, with the company highlighting a smoother pharmacokinetic profile compared with existing weekly GLP-1 injections.

The formulation uses an ultra-thin inorganic oxide coating to encapsulate the active ingredient, designed to control release over an extended period. In preclinical studies, Nanexa said the formulation showed a low ratio between maximum and minimum plasma concentration following once-monthly subcutaneous administration, with plasma levels described as more stable than those typically seen with weekly semaglutide dosing.

The company suggested that a lower initial plasma peak could reduce gastrointestinal adverse events commonly associated with GLP-1 therapies, including nausea. Nanexa also reported dose linearity and improved bioavailability compared with its earlier long-acting liraglutide formulation. The company said improved tolerability could support better treatment adherence, which remains a challenge for GLP-1 therapies.

Nanexa is shifting its development focus from liraglutide to semaglutide following these findings, citing the commercial and therapeutic interest in long-acting GLP-1 treatments. The semaglutide programme builds on Phase 1 data from the company’s liraglutide programme, which was presented in 2025 and used to refine modelling and formulation strategies.

David Westberg, ceo of Nanexa, said: “Demonstrating such a long release profile and low ratio between the maximum and minimum plasma concentration for monthly administration is exceptional and highlights how powerful the PharmaShell technology can be for complex molecules like semaglutide. We are excited about this data which will strengthen our position to secure commercial partnerships.”

The company has not disclosed timelines for clinical development of the semaglutide formulation but framed the data as supporting further progression towards clinical readiness. While the findings are preclinical, the results align with broader industry efforts to extend dosing intervals for GLP-1 therapies and differentiate next-generation formulations through improved tolerability and adherence profiles.

Nanexa’s announcement includes promotional language around partnership potential, indicating a commercial positioning element alongside the scientific update. However, the data itself reflects early-stage research rather than clinical outcomes, and further studies will be required to confirm safety, tolerability and efficacy in humans.